Rapamycin suppresses experimental aortic aneurysm growth.

[1]  T. Greiner,et al.  Key Roles of CD4+ T Cells and IFN-γ in the Development of Abdominal Aortic Aneurysms in a Murine Model1 , 2004, The Journal of Immunology.

[2]  M. Aoki,et al.  Inhibition of Experimental Abdominal Aortic Aneurysm in the Rat by Use of Decoy Oligodeoxynucleotides Suppressing Activity of Nuclear Factor &kgr;B and ets Transcription Factors , 2003, Circulation.

[3]  B. Zuckerbraun,et al.  Overexpression of mutated IκBα inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation , 2003 .

[4]  Gorav Ailawadi,et al.  Current concepts in the pathogenesis of abdominal aortic aneurysm. , 2003, Journal of vascular surgery.

[5]  P. Serruys,et al.  New frontiers in cardiology: drug-eluting stents: Part II. , 2003, Circulation.

[6]  Patrick W Serruys,et al.  New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.

[7]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[8]  M. Nicholson,et al.  Sirolimus attenuates the expression of metalloproteinase-2 and -9 and inhibits intimal hyperplasia following balloon angioplasty. , 2002, Transplantation proceedings.

[9]  Robert W. Thompson,et al.  Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. , 2002, Journal of vascular surgery.

[10]  Janita F. J. Vos,et al.  Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.

[11]  J D Humphrey,et al.  Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. , 2001, Journal of vascular surgery.

[12]  A. Newby,et al.  Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. , 2001, Cardiovascular research.

[13]  D. Carey,et al.  Elastase is not sufficient to induce experimental abdominal aortic aneurysms. , 2001, Journal of vascular surgery.

[14]  David C. Han,et al.  Inhibition of inducible nitric oxide synthase limits nitric oxide production and experimental aneurysm expansion. , 2001, Journal of vascular surgery.

[15]  G. Berry,et al.  SIROLIMUS (RAPAMYCIN) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1 , 2000, Transplantation.

[16]  U. Christians,et al.  Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  L. Golub,et al.  Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. , 1998, Journal of vascular surgery.

[18]  P. Baeuerle.  IκB–NF-κB Structures At the Interface of Inflammation Control , 1998, Cell.

[19]  S. Bryant,et al.  Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. , 1997, The American journal of pathology.

[20]  G. Nabel,et al.  Regulation of NF-κB by Cyclin-Dependent Kinases Associated with the p300 Coactivator , 1997, Science.

[21]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[22]  W. Parks,et al.  Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. , 1996, Journal of vascular surgery.

[23]  V. Dzau,et al.  Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. , 1995, Transplantation.

[24]  G. Chejfec,et al.  Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. , 1992, Journal of vascular surgery.

[25]  D. Carey,et al.  The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. , 1999, Journal of vascular surgery.

[26]  P. Baeuerle.  IkappaB-NF-kappaB structures: at the interface of inflammation control. , 1998, Cell.